In a phase 2 study in PSC patients without cirrhosis, the authors found that 100 mg cilofexor administration for 12 weeks significantly improved biochemical indicators and showed a weak downward trend in liver fibrosis indicators TIMP-1 (Trauner et al., 2019), they continued to give cilofexor treatment for 96 weeks, and they found that cilofexor retained the improvement of liver biochemistry but increased the enhanced liver fibrosis score (Trauner et al., 2023). The gene discussed is TIMP1; the disease is Hepatic fibrosis.